J&J eyes $100B in sales amid gains for cancer, immune drugs

Amid patent expirations, litigation and tariff costs, J&J says it expects more growth ahead, fueled in part by its blood cancer medicines and a closely watched psoriasis pill.

By Kristin Jensen • Jan. 21, 2026

Valneva to withdraw Chikungunya vaccine from US amid safety woes

The decision comes months after the FDA had suspended the vaccine’s license. One analyst speculated the company might shelve the product altogether. 

By Delilah Alvarado • Jan. 20, 2026

Explore the Trendline➔

Top 5 stories from BioPharma Dive

Looming patent expiries this decade and intensifying competition from China are forcing drugmakers to adapt, while new opportunities open up in oncology and in neuroscience.

By BioPharma Dive staff

GSK to buy Rapt in $2.2B deal for food allergy drug

The deal is the first for new CEO Luke Miels as the British drugmaker looks to overcome pressure on its HIV and vaccines businesses.

By Kristin Jensen • Jan. 20, 2026

Tecvayli tops standard drugs in early multiple myeloma, J&J says

The results build on evidence U.S. regulators found so compelling last year they proactively awarded J&J a new kind of drug review voucher. 

By Jonathan Gardner • Jan. 15, 2026

JPM26: Paying cash for obesity drugs, renewed IPO optimism and pharma’s cell therapy view

Drugmaker CEOs see online sales channels as a budding opportunity, while some biotech investors told BioPharma Dive to expect a rebound in new stock offerings. 

By BioPharma Dive staff • Jan. 14, 2026

Lilly, chasing Novo, expects second-quarter FDA decision on obesity pill

Speaking at the J.P. Morgan conference, CEO David Ricks said he anticipates a “rapid review” for orforglipron that's currently speeding along “at pace.” 

By Jonathan Gardner • Jan. 14, 2026

JPM26: Biotech’s M&A lift, the ‘new’ Biogen and Merck’s $70B target

Venture investors are adopting a more aggressive mindset heading into 2026, while Merck, Moderna and Summit are all approaching crucial trial readouts.

By BioPharma Dive staff • Jan. 13, 2026

What Sanofi’s multiple sclerosis troubles could mean for the space

Regulatory and clinical roadblocks have set back its oral BTK inhibitor tolebrutinib, but the drug class still has many opportunities to make an impact.

By Kelly Bilodeau • Jan. 13, 2026

AbbVie pledges $100B to US production in drug pricing deal with Trump

As with the many other “most-favored-nation” deals between the White House and large pharmas, the agreement is short on details as well as its potential financial impact.

By Ben Fidler • Jan. 13, 2026

JPM26: US biotech’s ‘Sputnik moment,’ Pfizer’s obesity ambitions and Bristol Myers’ big year

Four recent deals fueled more angst about China’s biotech progress, while Pfizer, Bristol Myers and Sarepta all worked to appease jittery investors. 

By BioPharma Dive staff • Jan. 12, 2026

5 questions facing biopharma in 2026

The biopharmaceutical sector finally regained its footing in 2025. Here are five issues that could determine whether the renewed optimism will carry over into the new year.

By BioPharma Dive staff • Jan. 12, 2026

Lilly snaps up Ventyx for $1.2B in pursuit of oral immune drugs

The buyout is a bet by Lilly on an increasingly popular drug target known as NLRP3 inflammasomes, which are implicated in an array of conditions.

By Jonathan Gardner • Updated Jan. 8, 2026

CDC, following Trump’s orders, weakens US stance on childhood vaccinations

In a drastic decision made outside of its typical review process, the agency declared it would recommend 11 childhood shots going forward, down from 17.

By Delilah Alvarado • Updated Jan. 6, 2026

Surfing the AI wave: How pharma can harness agents in ERP

AI is reshaping pharma faster than any tech wave before. Learn where to start and how to scale.

By Thomas Van Dorpe • Jan. 5, 2026

Novo Nordisk’s weight loss pill approved by FDA

The clearance brings an oral form of Novo’s Wegovy to market ahead of Lilly’s rival medication and kicks off the next phase of an escalating battle for control of the obesity drug market. 

By Jonathan Gardner • Dec. 23, 2025

Biopharma CEO optimism is wavering in the US

The overall leadership outlook was positive in a recent survey but varied between executives in the U.S. and those overseas.

By Kelly Bilodeau • Dec. 23, 2025

Biopharma climbs higher as 9 drugmakers ink ‘pandering’ drug price deals with Trump

Analysts see little effect on the bottom lines of biopharma companies, as they stand to stave off tariff pressure and receive other benefits from the agreements.

By Kristin Jensen • Dec. 22, 2025

Novo files for CagriSema approval; Merck and Pfizer’s trial win

Novo Nordisk's application for CagriSema comes at the same time as competitor Eli Lilly's ask for its obesity drug orforglipron. Elsewhere, Merck & Co. and Pfizer succeeded in a bladder cancer study.

By BioPharma Dive staff • Dec. 19, 2025

Lilly obesity pill, headed for quick FDA review, hits mark in ‘maintenance’ trial

Orforglipron helped keep weight down when used after initial therapy with an injectable, a new treatment strategy that could broaden its use in obesity. 

By Jonathan Gardner • Dec. 18, 2025

FDA clears GSK’s twice-yearly asthma drug

Exdensur is now the first asthma biologic to be approved for twice-yearly dosing, and could potentially change standard of care for those with severe disease.

By Delilah Alvarado • Updated Dec. 17, 2025

Sanofi MS drug hits two setbacks

Tolebrutinib, which Sanofi acquired in a $3.7 billion buyout, failed a Phase 3 study in “primary progressive” multiple sclerosis and is facing a delayed U.S. approval decision in another form of the disease.

By Jacob Bell • Dec. 15, 2025

Novartis notches another win for drug acquired in MorphoSys deal

Ianalumab, which has already succeeded in testing against Sjogren’s syndrome, proved impactful in a condition that causes low platelet counts.

By Jonathan Gardner • Dec. 9, 2025

Pfizer dips into China for another try at an obesity pill

A potentially $2 billion deal with a subsidiary of Shanghai-based Fosun Pharma gives Pfizer a new chance at an oral weight loss medication, an area where its internal research has struggled.

By Kristin Jensen • Dec. 9, 2025

FDA raises CAR-T approval standards; Novartis bets on an AI startup

CAR-T cancer therapies now need to succeed in randomized, controlled trials to earn approvals. Elsewhere, a drug from Bristol Myers Squibb and BioNTech proved effective in breast cancer patients.

By BioPharma Dive staff • Dec. 9, 2025

J&J’s ‘remarkable’ Tecvayli data support earlier use in multiple myeloma

In a step forward for bispecific antibodies, study results presented at ASH suggest a Tecvayli-based combination could have curative potential early in a patient’s disease course.

By Jonathan Gardner • Dec. 9, 2025